Molecules having MAO-A inhibition characteristics are utilized as antidepressants while molecules with MAO-B inhibition prospective are utilized to treat Parkinson's and Alzheimer's diseases. Here, MAOA is linked to early-onset autosomal dominant Alzheimer disease.